Skip to main content

2025 PharmSci 360 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

U
W0930-06-34
Ultraflexible Liposomes Enhance Topical Delivery of ADT-007 for Potential Melanoma Therapy

Favorite
T1130-03-19
Ultrasensitive LC-MS/MS Method Enables a Thorough Pharmacokinetic Investigation of Low-Dose Semaglutide Following Oral and Subcutaneous Administration in Healthy Subjects

Favorite
T1330-03-21
Ultrasound Responsive Violacein Loaded Liposomes for Sonodynamic Therapy against Broad-Spectrum Bacteria and Melanoma: In Vitro Studies

Favorite
M1130-02-10
Understanding How UHPLC System Characteristics Effect “Going Green” with Regulated Methods

Favorite
M1130-08-49
Understanding Stabilization Potential of Polymeric Excipients for Spray-Dried Monoclonal Antibody Formulations

Favorite
T1030-02-09
Understanding the Compatibility of CSTDs with Container Closure Systems in Accordance with USP < 382 > to Meet Functionality Requirements

Favorite
T1230-06-39
Understanding the Interplay between Formulation and Process Variables to Fabricate Combination Printlets of Lamivudine and Tenofovir Disoproxil Fumarate for Pediatric Populations

Favorite
T1230-02-10
Unraveling the Bridging Region of Lenacapavir Atropisomers by 2D-LC

Favorite
M1130-09-55
Unraveling the Impact of Ionic Strength on Antibody Self-Association Using a Novel QCM-D Approach

Favorite
M1530-01-01
Untargeted Lipidomics Identifies Distinct Metabolic Alterations in Huh-7 Hepatocellular Carcinoma Cells Receiving Monotherapy or Combination Therapy with Atorvastatin and Doxorubicin

Favorite
M1530-03-17
Unveiling PNAG Dynamics in Bacterial Biofilms through Microfluidics and Fluorescence Microscopy

Favorite
T1230-02-08
UPLC Investigation for Understanding Excipient Interactions to Enhance Stability in a Transdermal Apixaban Delivery System

Favorite
T1330-06-36
Urolithin A-Laden P2Ns-GA Enhances Anticancer Efficacy in Cisplatin-Resistant Ovarian Cancer and Mitigate Nephrotoxicity in a Murine Model

Favorite
W1130-07-43
Urolithin-A Laden Nanoparticles Attenuate Cisplatin-Induced Systemic Toxicity: A Comparative Study in Aged and Young Mice

Favorite
M0930-07-41
Use of 5% Dextrose Intravenous Diluent for Therapeutic Monoclonal Antibodies: Impact on Mabs Under Varying Formulation Conditions

Favorite
T1330-09-60
Use of PBBM-PBPK to Predict Mesalamine Delayed-Release Oral Drug Products Performance in Both Healthy and Disease Physiologies

Favorite
W0930-05-31
User-Friendly Web Applications for Pharmacokinetic Simulations and Predictions

Favorite
T1430-05-28
Utilizing PBPK Modeling in GastroPlus to Explore the Pharmacogenetics of Gisenoside Rd

Favorite